The Weekly Roundup: February 7-11

ICYMI, this week we had stories on the newest FDA approvals, biologic therapy in plaque psoriasis, and more.

POLL: Which AD comorbidities were most interesting?

Biologic Therapy in Plaque Psoriasis: Treating During the COVID-19 Pandemic

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

Plaque Psoriasis Management: Future Directions in Care

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.

JAK Inhibitors: An Overview

James Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.

The Mainstream Patient: February 8

This week's edition of the Mainstream Patients features stories about the benefits of castor oil, the controversy of fragranced skin care, and more.

FDA Approves Juvéderm Volbella XC for Undereye Hollows

Allergan Aesthetics, an AbbVie company, announced the FDA approval of Juvéderm Volbella XC for undereye hollows.

Pointers with Dr Portela: How to Spot a Counterfeit Laser

In this week’s Pointers with Dr Portela, the 208SkinDoc highlights a growing issue of lasers made to look like or mimic the technology of already approved lasers but can have dangerous consequences.

LEO Pharma Presents New Tralokinumab-ldrm Data

Tralokinumab-ldrm (Adbry; LEO Pharma) showed improvement in itch, sleep, anxiety, depression, and overall quality of life data for adolescent AD patients in newly released study data.

4 tips to curbing rising costs and staffing shortfalls

Medical networks and smaller practices alike are facing spiraling inflation costs and staffing shortfalls due to waves of COVID cases that are impacting physicians, staff, and management.

Pressure mounts on Congress to enact telehealth reform

Two letters ask that pandemic-era flexibilities become permanent.

Dupilumab Receives FDA Priority Review and Accepts sBLA for Children 6 Months to 5 Years

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.

Survey: Pandemic’s Impact on Dermatology Practices and Patients

The American Society for Dermatologic Surgery investigated how the COVID-19 pandemic affected both dermatology practices and patients from staffing reductions to telehealth.

Groundbreaking AAD Guidelines Assess Links Between AD, Comorbidities

The American Academy of Dermatology’s newest guideline focuses on awareness of other health conditions associated with atopic dermatitis in adult patients.

Survey: Demand for Facial Plastic Surgery Surged In 2021

The results from the American Academy of Facial Plastic and Reconstructive Surgery annual survey showed an uptick in demand for facial plastic surgery, an increase in popularity for lifts and lasers, and a growing gender neutrality in patients.